We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+20.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$460M
AUM Growth
-$24.7M
Cap. Flow
-$63.4M
Cap. Flow %
-13.79%
Top 10 Hldgs %
55.03%
Holding
52
New
9
Increased
6
Reduced
21
Closed
13

Top Buys

1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$24.2M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$16.9M
3
AGN
Allergan plc
AGN
+$15.9M
4
SIEN
Sientra, Inc.
SIEN
+$10.1M
5
HRTX icon
Heron Therapeutics
HRTX
+$8.99M

Top Sells

1
IOVA icon
Iovance Biotherapeutics
IOVA
+$41.7M
2
CPRX icon
Catalyst Pharmaceutical
CPRX
+$13.4M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.2M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$11.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.5M

Sector Composition

1 Healthcare 78.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
26
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.98M 1.3%
15,994
-11,472
-42% -$4.1M
ATRS
27
DELISTED
Antares Pharma, Inc.
ATRS
$5.74M 1.25%
1,744,147
-899,800
-34% -$2.6M
INCY icon
28
Incyte
INCY
$23.4B
$5.66M 1.23%
66,600
-33,400
-33% -$2.68M
AMRN
29
Amarin Corp
AMRN
$292M
$5.64M 1.23%
+14,550
New +$5.33M
VCEL icon
30
Vericel Corp
VCEL
$2.38B
$4.88M 1.06%
258,150
-14,400
-5% -$246K
OPTN
31
DELISTED
OptiNose
OPTN
$4.22M 0.92%
39,727
+687
+2% +$90.5K
WMGI
32
DELISTED
Wright Medical Group Inc
WMGI
$3.77M 0.82%
+126,400
New +$3.86M
MYGN icon
33
Myriad Genetics
MYGN
$584M
$3.44M 0.75%
123,785
-116,215
-48% -$3.28M
TVTX icon
34
CALL
Travere Therapeutics
TVTX
$5.27B
$3.01M 0.66%
+150,000
New +$2.96M
ADMA icon
35
ADMA Biologics
ADMA
$2.02B
$2.89M 0.63%
747,500
-731,743
-49% -$3.23M
ADMS
36
DELISTED
Adamas Pharmaceuticals
ADMS
$2.73M 0.6%
441,088
-2,028,806
-82% -$11.7M
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$2.27M 0.49%
74,786
-280,928
-79% -$7.44M
HRTX icon
38
CALL
Heron Therapeutics
HRTX
$89.1M
$1.86M 0.4%
100,000
-300,000
-75% -$5.99M
MTNB icon
39
Matinas BioPharma
MTNB
$2.2M
$657K 0.14%
15,334
-39,211
-72% -$1.88M
ACRS icon
40
Aclaris Therapeutics
ACRS
$793M
– –
-2,030,925
Closed -$12.2M
ATEC icon
41
Alphatec Holdings
ATEC
$1.31B
– –
-442,966
Closed -$1.17M
IART icon
42
Integra LifeSciences
IART
$1.5B
– –
-141,572
Closed -$7.89M
LIVN icon
43
LivaNova
LIVN
$4.43B
– –
-48,000
Closed -$4.67M
MYGN icon
44
CALL
Myriad Genetics
MYGN
$584M
– –
-500,000
Closed -$16.6M
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-148,100
Closed -$11.5M
RVLP
46
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-307,854
Closed -$1.11M
OPNT
47
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-85,484
Closed -$1.12M
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-120,746
Closed -$8.26M
XENT
49
DELISTED
Intersect ENT, Inc
XENT
– –
-263,500
Closed -$8.47M
TLGT
50
DELISTED
Teligent, Inc
TLGT
– –
-199,098
Closed -$2.31M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Broadfin Capital held 52 positions worth $460M, down 5.1% from $484M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $63.4M in Q2 2019, closing 13 positions and reducing 21 holdings. Its most notable exit was Aclaris Therapeutics, an estimated $12.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Allergan plc worth $19.2M.

  • Broadfin Capital's largest Q2 2019 buy was Allergan plc: 114,804 shares worth $19.2M.
  • Broadfin Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $24.2M increase.
  • Broadfin Capital's biggest Q2 2019 reduction was Iovance Biotherapeutics, cutting an estimated $41.7M.
  • Broadfin Capital fully exited Aclaris Therapeutics in Q2 2019, selling an estimated $12.2M.
  • Broadfin Capital's ten largest holdings make up 55% of its $460M portfolio in Q2 2019.
  • Broadfin Capital opened 9 new positions and closed 13 in Q2 2019.
  • Broadfin Capital's portfolio value fell 5.1% quarter-over-quarter to $460M.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.